A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
NCT ID: NCT00749632
Last Updated: 2009-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
45 participants
INTERVENTIONAL
2007-07-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
NCT04090190
A Safety Extension Study of DR-OXY-301
NCT00782769
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
NCT00909181
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636
Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence
NCT00304499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
oxybutynin
low dose oxybutynin administered daily
2
oxybutynin
middle dose oxybutynin administered daily
3
oxybutynin
high dose oxybutynin administered daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oxybutynin
low dose oxybutynin administered daily
oxybutynin
middle dose oxybutynin administered daily
oxybutynin
high dose oxybutynin administered daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has reported symptoms of urge urinary incontinence/overactive bladder
Exclusion Criteria
* Has had lower urinary tract surgery within 6 months prior to Screening
* Has a history of urinary retention
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FemmePharma Global Healthcare, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
FemmePharma Global Healthcare, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter K. Mays, Ph.D.
Role: STUDY_DIRECTOR
FemmePharma Global Healthcare, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SNBL Clinical Pharmacology Center
Baltimore, Maryland, United States
Advanced Biomedical Research
Hackensack, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FP1097-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.